DeutschNewstral
Article
wsj.com on 2020-01-29 10:38
Novartis Posts Sales Growth as It Slims Down
Related news
- BNovartis Posts Strong Results, but Is Silent on Gene-Therapy Salesbarrons.com
Novartis slims down with $25bn spin-off of Alcon eyecare businessbusinessdayonline.com- MNovartis profit misses forecasts, but sales beatmarketwatch.com
Citigroup slims down, boosts profitsdothaneagle.com
Swiss biotech company Roche posts 4 percent sales growthkentucky.com- MNovartis net income climbs as drug sales growmarketwatch.com
- Novartis Rethinks Sales Strategy for New Cholesterol Drug Launchwsj.com
Citigroup slims down, boosts profit numbersThe Salt Lake Tribune- MNovartis says taxes hit fourth-quarter profit, but sees growth in 2020marketwatch.com
- MDrugmaker Novartis plays down its deal with Trump’s lawyer, tying it to its former CEOmarketwatch.com
- FNovartis faces possible S Korea sales banft.com
Novartis notches higher profit on strong salesthelocal.ch
Starbucks posts disappointing sales growthSan Jose Mercury News- ASwiss drugs giant Novartis posts 15 percent drop in profitapnewsarchive.com
Swiss pharma giant Novartis posts higher 2020 profittimesofmalta.com- MUber posts 55% jump in first-quarter sales, plans to double down on growthmarketwatch.com
Novartis profit slips as generic drug competition hits salesThe Findlay Courier- KGlobal Non Narcotic Analgesics Sales Market – Detailed analysis of current Industry figures with forecasts growth by 2028 | Top Players; Sanofi S.A., Novartis AG, GlaxoSmithKline PLC, Pfizer, Reckitt Benckiser, Endo Pharmaceuticals, and moreksusentinel.com
- Novartis Earnings Fall on Slide in Cancer-Drug Saleswsj.com
- Novartis sales rise as clients restock post-lockdowntimesofmalta.com